US Edition
Your source for latest news
BusinessAntitrust

FTC sues to block Covetrus's $3.5 billion acquisition of rival veterinary distributor MWI

The agency and 13 states argue the deal would combine the two largest national distributors of veterinary supplies, raising costs for clinics and, eventually, pet owners already paying more for animal care.

PB
By PressTemps Business DeskPublished November 14, 2026 · 5 min read
FTC sues to block Covetrus's $3.5 billion acquisition of rival veterinary distributor MWI
The Federal Trade Commission's headquarters in Washington, D.C. The agency sued November 13 to block Covetrus's acquisition of MWI Veterinary Supply. Photo: Blue MauMau / Flickr (CC BY 2.0).
What to know
The FTC and 13 state attorneys general sued November 13 in the Southern District of New York to block Covetrus's $3.5 billion acquisition of MWI Veterinary Supply from Cencora, voting 2-0 to seek a permanent injunction.
The agency alleges Covetrus and MWI are each other's closest rivals in two concentrated markets — distribution to individual veterinary clinics and to large corporate veterinary accounts — and have been engaged in an "all-out price war."
Under the February merger agreement, Cencora was set to receive $1.25 billion in cash plus preferred and common equity worth $2.25 billion combined, retaining a 34.3% stake in the combined company; that payout is now in doubt.
Covetrus says the FTC's market definition is "narrow and outdated," citing online price-comparison platforms used by more than 60% of U.S. veterinary practices, and says it will fight the case in court.

The Federal Trade Commission sued Friday to block Covetrus Inc.'s $3.5 billion acquisition of MWI Veterinary Supply Inc., arguing that combining the two largest national distributors of veterinary products would let the merged company raise costs for clinics and, eventually, pet owners. The complaint, filed in the U.S. District Court for the Southern District of New York, names Covetrus; its private-equity owners, Clayton, Dubilier & Rice and TPG; and Cencora Inc., the drug distributor that has owned MWI since 2015. Thirteen state attorneys general, including those of California, New York and Texas, joined the action.

The Commission voted 2-0 to authorize staff to seek a permanent injunction, according to the case filing listed on the FTC's website. The vote count reflects a two-member commission; the agency has operated without its full slate of five commissioners for much of the year.

What the FTC alleges

The agency's complaint identifies two relevant markets: distribution of pharmaceuticals, vaccines, surgical supplies and other products to individual veterinary clinics, and distribution to large corporate veterinary accounts that operate hundreds of locations. Covetrus and MWI are each other's closest rivals in both, the FTC says, and have spent years locked in what the complaint calls an "all-out price war," intensified by Vetcove, an online marketplace that lets clinics compare distributor pricing in real time and use one supplier's quote to negotiate a better deal from the other.

The agency argues that specialty distributors, drug manufacturers selling directly to clinics, and retailers are not close enough substitutes to restrain pricing by the two dominant national networks, and that structural barriers make it difficult for a new competitor to build comparable scale. Combined with existing concentration in both markets, the FTC says, the merger is presumptively unlawful under the 2023 merger guidelines it issued jointly with the Justice Department.

"Covetrus wants to eliminate its closest competitor rather than compete for veterinary clinic customers," said Daniel Guarnera, director of the FTC's Bureau of Competition, who also said the deal "will reduce competition in an already concentrated market."

The deal and the companies

Covetrus and MWI Animal Health agreed in February to merge into a single company, according to a Cencora securities filing. Under the terms disclosed in that filing, Cencora would receive $1.25 billion in upfront cash, $800 million in preferred equity and $1.45 billion in common equity in the combined business, leaving it with a 34.3 percent noncontrolling stake. Cencora, a Fortune 500 pharmaceutical distributor, had said the animal-health unit no longer fit its long-term strategy and planned to use the proceeds to focus on its core drug-distribution business. Covetrus, based in Portland, Maine, has been owned by the private equity firms Clayton, Dubilier & Rice and TPG since a 2022 take-private deal.

Both companies run national networks that ship pharmaceuticals, vaccines, so-called "white goods" such as gloves and syringes, and thousands of other products to veterinary practices, along with inventory-management and rebate programs. The FTC's complaint says those loyalty and volume discounts, run through programs including Covetrus's VetSuite, are themselves a competitive weapon the companies use against each other that a merger would eliminate.

Who is affected

The case turns on the roughly 30,000 veterinary practices in the United States, ranging from single-doctor clinics to corporate chains with hundreds of locations, that rely on national distributors for day-to-day supplies. The FTC's theory is that reduced competition between Covetrus and MWI would translate into higher prices and worse service for those practices, costs that veterinarians would likely pass on to pet owners already contending with rising costs for routine and emergency animal care.

  • Independent and corporate veterinary clinics that currently play Covetrus and MWI pricing against each other through platforms such as Vetcove
  • Pet owners, who the FTC says would ultimately absorb higher distribution costs through clinic fees
  • Cencora shareholders, whose expected cash and equity proceeds from the sale are now in question
  • Clayton, Dubilier & Rice and TPG, Covetrus's private-equity owners, who would need to find another path to realize value from the company absent the merger

Reaction and what comes next

Covetrus pushed back on the agency's market definition, according to reporting from the trade publication dvm360, calling the FTC's view of the market "narrow and outdated" and saying it does not reflect how veterinarians actually buy supplies. The company said more than 60 percent of U.S. practices already use online marketplaces to compare prices across more than 40 distributors, that manufacturers frequently sell directly to clinics, and that other national and regional distributors compete for both individual and corporate accounts. Covetrus said it is prepared to defend the merger in court and argued the combination "stands to improve the economics of veterinary practices." Cencora and MWI had not issued their own public statements as of Friday evening.

The filing follows months of regulatory scrutiny. Bloomberg Law reported that the companies had offered the agency and state regulators a package of proposed remedies last month in an attempt to avoid litigation, an effort that evidently fell short. A trial date has not been set. The FTC is seeking a permanent injunction that would block the transaction outright rather than require the companies to sell off assets, meaning the case is likely to be litigated as an all-or-nothing contest over whether the deal can close at all. Cencora's most recent financial guidance already assumed the transaction would not close before the end of its fiscal year in September, so a protracted court fight would extend a timeline that was already uncertain.

More on this story

All Business